Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Moderate Buy” by Analysts

Oculis Holding AG (NASDAQ:OCS) has received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $41.50.

A number of research analysts recently issued reports on OCS shares. Stifel Nicolaus raised their target price on shares of Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. initiated coverage on Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Finally, Lifesci Capital initiated coverage on Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 target price on the stock.

Hedge Funds Weigh In On Oculis

Large investors have recently bought and sold shares of the stock. Compagnie Lombard Odier SCmA grew its position in Oculis by 11.5% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after purchasing an additional 10,000 shares during the last quarter. Woodline Partners LP lifted its stake in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares during the period. Bank of America Corp DE grew its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Geode Capital Management LLC increased its stake in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the period. Finally, Marshall Wace LLP acquired a new position in Oculis in the 2nd quarter valued at approximately $393,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Stock Up 4.7%

Shares of OCS stock opened at $23.07 on Friday. The stock’s 50 day simple moving average is $19.92 and its 200 day simple moving average is $18.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. Oculis has a twelve month low of $14.00 and a twelve month high of $23.99. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -9.15 and a beta of 0.31.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The firm had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.23 million. As a group, research analysts predict that Oculis will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.